Skip to main content

Table 1 Inclusion and exclusion criteria

From: Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients—a randomized rater-blinded trial

Inclusion criteria

Age

 ≥ 18– ≤ 70

Sex

Male, female, or diverse

Major depressive episode according to ICD-10 (F32.2–3, F33.2–3)

Single or recurrent episodes, as confirmed by the DIPS

Symptom severity

Severe (MADRS ≥ 34)

Modification in the therapeutic regimen is being considered

e.g., change of AD or change to neuromodulatory therapy

First MDD episode < 50 years

 

Capacity for consent

 

Written informed consent

 

Exclusion criteria

 Acute suicidality

 

 Accommodation according to state law

(e.g., §16/17 Nds. PsychKG)

 Persistent depressive disorder (PDD) (ICD-10: F34.1)

 

 (Lifetime) diagnoses of

Dementia, schizophrenia, schizoaffective disorder, bipolar disorder, substance addiction with currently necessary detoxification

 Simultaneous participation in other clinical trials that are not conducted within the scope of the P4D project

 
  1. Abbreviations: AD antidepressant drug(s), AE adverse event, ICD-10 10th revision of the International Statistical Classification of Diseases and Related Health Problems, MADRS Montgomery–Åsberg Depression Rating Scale, MDD major depressive disorder, Nds. PsychKG Lower Saxony Law on Assistance and Protective Measures for the Mentally Ill